详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)

47| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, [2]Department of Pulmonary Disease, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, [3]Department of Respiratory Medicine, Institute of Respiratory Diseases, The First Affiliated Hospital of China Medical University, Shenyang, [4]Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing, [5]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, [6]Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, [7]Department of Respiratory Medicine, Qilu Hospital of Shandong University, Jinan, [8]Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, [9]Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, [10]Division of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of China

出处：

DOI：

ISSN：

关键词： mucus COPD asthma bronchiectasis cystic fibrosis treatment

摘要：

Airway mucus hypersecretion is one of the most important characteristics of chronic airway inflammatory diseases. Evaluating and managing airway mucus hypersecretion is of great importance for patients with chronic airway inflammatory diseases. This consensus statement describes the pathogenesis, clinical features, and the management of airway mucus hypersecretion in patients with chronic airway inflammatory diseases in the People's Republic of China. The statement has been written particularly for respiratory researchers, pulmonary physicians, and patients.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 3 区医学

小类 | 3 区呼吸系统

最新[2025]版：

大类 | 3 区医学

小类 | 3 区呼吸系统

JCR分区：

出版当年[2016]版：

Q2 RESPIRATORY SYSTEM

最新[2023]版：

Q2 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 2.7 最新五年平均[2021-2025] 2.9 出版当年[2016版] 3.157 出版当年五年平均[2012-2016] 3.284 出版前一年[2015版] 3.046 出版后一年[2017版] 2.917

第一作者：

第一作者单位： [1]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu,

通讯作者：

通讯机构： [1]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, [*1]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, No 37, Guo Xue Xiang, Chengdu 610041, People’s Republic of China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)

文献详情

相关文献